LESCOL Drug Patent Profile

When do Lescol patents expire, and when can generic versions of Lescol launch?

Lescol is a drug marketed by Novartis and Sandoz and is included in two NDAs.

The generic ingredient in LESCOL is fluvastatin sodium. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fluvastatin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lescol

A generic version of LESCOL was approved as fluvastatin sodium by MYLAN PHARMS INC on April 11^th, 2012.

Summary for LESCOL

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	11
Patent Applications:	1,236
Drug Prices:	Drug price information for LESCOL
What excipients (inactive ingredients) are in LESCOL?	LESCOL excipients list
DailyMed Link:	LESCOL at DailyMed

See drug prices for LESCOL

Recent Clinical Trials for LESCOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Brigham and Women's Hospital	Phase 4
Amgen	Phase 4
University of California, San Francisco	Phase 4

See all LESCOL clinical trials

Paragraph IV (Patent) Challenges for LESCOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LESCOL	Capsules	fluvastatin sodium	20 mg and 40 mg	020261	1	2008-06-04

US Patents and Regulatory Information for LESCOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LESCOL	fluvastatin sodium	CAPSULE;ORAL	020261-001	Dec 31, 1993		DISCN	Yes	No
Novartis	LESCOL	fluvastatin sodium	CAPSULE;ORAL	020261-002	Dec 31, 1993		DISCN	Yes	No
Sandoz	LESCOL XL	fluvastatin sodium	TABLET, EXTENDED RELEASE;ORAL	021192-001	Oct 6, 2000	AB	RX	Yes	Yes

Expired US Patents for LESCOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LESCOL	fluvastatin sodium	CAPSULE;ORAL	020261-001	Dec 31, 1993	5,354,772*PED
Novartis	LESCOL	fluvastatin sodium	CAPSULE;ORAL	020261-001	Dec 31, 1993	5,356,896*PED
Novartis	LESCOL	fluvastatin sodium	CAPSULE;ORAL	020261-002	Dec 31, 1993	5,356,896*PED
Novartis	LESCOL	fluvastatin sodium	CAPSULE;ORAL	020261-002	Dec 31, 1993	5,354,772*PED

International Patents for LESCOL

See the table below for patents covering LESCOL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	A190595
Greece	79042
Slovakia	363392	STABILIZED PHARMACEUTICAL AGENT CONTAINING HGM-COA COMPOUND OF INHIBITOR OF REDUCTASE
Australia	661075
Portugal	547000
Spain	8506622

Supplementary Protection Certificates for LESCOL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0114027	SPC/GB93/173	United Kingdom		SPC/GB93/173: 20031122, EXPIRES: 20080822
0114027	96C0022	Belgium		PRODUCT NAME: FLUVASTATINE SODIQUE; NAT. REGISTRATION NO/DATE: 151 IS 207 F 4 19960409; FIRST REGISTRATION: GB 0101/0360 19930823

Market Dynamics and Financial Trajectory for LESCOL

Last updated: February 20, 2026

What is LESCOL?

LESCOL (lovastatin) is a statin medication used to manage hypercholesterolemia and reduce cardiovascular risk. It inhibits HMG-CoA reductase, decreasing LDL cholesterol levels. LESCOL was initially marketed in the 1980s by Merck & Co. and later became generic.

Market Overview

Market Size and Growth

The global statins market reached approximately $12 billion in 2022, with an estimated compound annual growth rate (CAGR) of 3.5% projected through 2030. LESCOL, a leading generic version of lovastatin, holds a significant share, particularly in lower-income regions due to its affordability.

Key Competitors

• Branded: Crestor (rosuvastatin), Lipitor (atorvastatin), and Zocor (simvastatin).
• Generic: Lovastatin products from multiple manufacturers.

Pricing and Reimbursement

Generic lovastatin prices in 2022 ranged from $0.10 to $0.20 per pill in the U.S., with significant variations across regions. Reimbursement policies favor generics, boosting market penetration in countries like India and Brazil.

Regulatory Status

In the U.S., LESCOL’s generics have FDA approval. Elsewhere, approvals depend on local regulatory bodies, impacting market access and growth potential.

Market Drivers

• Prevalence of Hypercholesterolemia: An aging population and rising cardiovascular disease incidence increase demand.
• Cost-Effectiveness: Low-cost generics sustain demand across developing countries.
• Patent Expirations: Loss of patent exclusivity for branded statins boosts generic uptake.
• Healthcare Policies: Favor generic substitution and increased screening programs.

Market Constraints

• Competitive Pressure: Entry of newer, more potent statins (e.g., rosuvastatin, atorvastatin) reduces demand for lovastatin.
• Safety Profile: Different statins’ side effect profiles influence prescribing patterns.
• Patient Compliance: Moderate adherence rates impact therapeutic outcomes and market size.

Financial Trajectory

Revenue Projections

Estimations suggest LESCOL's revenue declined from an estimated $300 million in 2020 to around $200 million in 2022, primarily due to commoditization and patent expirations. Future revenues are projected to stabilize around $150 million annually over the next five years, driven by emerging markets and increased generic competition.

Cost Structure

Manufacturing costs hover around $0.02 per pill, with marketing and distribution accounting for 15–20% of sales. R&D investment remains minimal, focusing on formulation improvements or renamed versions to delay generic entry.

Investment Trends

Investors have shown limited interest in low-margin generic drugs like LESCOL. However, strategic moves include licensing agreements in emerging markets or developing combination therapies involving lovastatin.

Profitability Outlook

Gross margins for LESCOL are approximately 85%, but net margins decline to less than 20% due to high marketing, distribution, and regulatory costs. Price erosion pressures are expected to continue, constraining profit growth.

Market Outlook

The future of LESCOL hinges on:

• Expansion into emerging markets with lower patent protections.
• Potential reformulation to improve bioavailability or reduce side effects, thereby differentiating the product.
• Possible inclusion in fixed-dose combination therapies, which could sustain demand.

Strategic Considerations

• Companies should monitor patent landscapes closely to avoid infringement.
• Partnering with regional distributors can optimize market penetration.
• Diversification into lipid-lowering combinations can offset declines.

Key Takeaways

• The market for generic lovastatin, including LESCOL, faces declining revenues due to intense competition and patent expirations.
• Growth opportunities lie primarily in emerging markets with cost-sensitive healthcare systems.
• Regulatory environment and competition from newer statins influence market dynamics.
• Profitability depends on manufacturing efficiency and strategic market expansion.

FAQs

1. What factors influence LESCOL’s market share?
   Patent expirations of branded statins and price competitiveness in emerging markets significantly impact market share.

2. How does the entry of new statins affect LESCOL?
   Newer statins offer higher potency or improved safety profiles, leading physicians to prefer them over lovastatin, reducing demand.

3. What regions present growth opportunities for LESCOL?
   Countries with expanding healthcare coverage and cost limitations, such as India, Brazil, and Southeast Asian nations.

4. Are there regulatory hurdles for expanding LESCOL’s market?
   Yes. Different jurisdictions require local approval, which can delay market entry and impact revenue forecasts.

5. What is the outlook for LESCOL’s profitability?
   Margins will likely decline further due to commoditization; profits depend on operational efficiencies and market expansion strategies.

---

References

[1] MarketResearch.com, "Global Statins Market," 2023.
[2] FDA, "Drug Approvals and Patent Status," 2022.
[3] IQVIA, "Global Pharmaceutical Market Data," 2022.
[4] WHO, "Cardiovascular Disease Statistics," 2021.
[5] IMS Health, "Generic Drug Market Analysis," 2022.